# Carien L. Creutzberg

Source: https://onco.cc/people/carien-creutzberg/  
OnCo record `carien-creutzberg` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the PORTEC trials that defined who needs radiotherapy for endometrial cancer and brought molecular classification into treatment decisions.

## Summary

Carien Creutzberg led PORTEC-1, -2 and -3, the Dutch trials that established vaginal brachytherapy over external beam radiotherapy for intermediate-risk endometrial cancer and tested chemoradiotherapy for high-risk disease, and pioneered the integration of the TCGA molecular classification (POLE, MMRd, p53abn, NSMP) into the PORTEC-4a trial and ESGO-ESTRO-ESP guidelines. She co-leads the RAINBO platform of molecularly directed adjuvant trials.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: endometrial; radiotherapy; molecular-classification
- Role: Professor of Radiation Oncology, Leiden University Medical Center
- Specialisms: Endometrial cancer; Radiotherapy; Molecular classification; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Creutzberg%20CL%5BAuthor%5D%20PORTEC

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- technologies: [Brachytherapy](https://onco.cc/technologies/brachytherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- institutions: [Leiden University Medical Center](https://onco.cc/institutions/lumc-leiden/)
- trials: [PORTEC-3](https://onco.cc/trials/portec-3/)

---
JSON: https://onco.cc/api/v1/entities/carien-creutzberg.json